Abstract
Folic acid, transferrin and integrin alpha v beta 3 (αvβ3) receptors are overexpressed in various cancer cell lines. Ligands having high affinity for these receptors are often conjugated to nanocarriers to facilitate the tumor localization of therapeutic agents. In this review the use of these ligands for targeted delivery using liposomes, dendrimers and (N-(2- hydroxypropyl) methacrylamide) (HPMA) copolymers is discussed. Emphasis is placed on discussing drug delivery systems that have been optimized for in-vitro binding as well as in-vivo pharmacokinetics. Our aim is to understand the various factors influencing the targeting ability of nanocarriers.
Keywords: Polymeric drug delivery, liposomes, dendrimer, HPMA, folic acid, transferrin, integrin alpha v beta, tumor targeting, Polymers, micelles
Current Drug Discovery Technologies
Title: Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Volume: 8 Issue: 3
Author(s): Rohit Kolhatkar, Asawari Lote and Hiren Khambhati
Affiliation:
Keywords: Polymeric drug delivery, liposomes, dendrimer, HPMA, folic acid, transferrin, integrin alpha v beta, tumor targeting, Polymers, micelles
Abstract: Folic acid, transferrin and integrin alpha v beta 3 (αvβ3) receptors are overexpressed in various cancer cell lines. Ligands having high affinity for these receptors are often conjugated to nanocarriers to facilitate the tumor localization of therapeutic agents. In this review the use of these ligands for targeted delivery using liposomes, dendrimers and (N-(2- hydroxypropyl) methacrylamide) (HPMA) copolymers is discussed. Emphasis is placed on discussing drug delivery systems that have been optimized for in-vitro binding as well as in-vivo pharmacokinetics. Our aim is to understand the various factors influencing the targeting ability of nanocarriers.
Export Options
About this article
Cite this article as:
Kolhatkar Rohit, Lote Asawari and Khambhati Hiren, Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors, Current Drug Discovery Technologies 2011; 8 (3) . https://dx.doi.org/10.2174/157016311796799044
DOI https://dx.doi.org/10.2174/157016311796799044 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Membrane Interacting Peptides: A Review
Current Protein & Peptide Science Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Aggrecanase: The Family and Its Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents G-Protein Coupled Receptor Resensitization - Appreciating the Balancing Act of Receptor Function
Current Molecular Pharmacology Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets
Current Pharmaceutical Design Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets Identification and Characterization of Follistatin-Related Protein-1 Involved in the Regulation of Chinese Perch Skeletal Muscle Hyperplasia
Current Molecular Medicine Thrombospondins as Anti-Angiogenic Therapeutic Agents
Current Pharmaceutical Design Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Cytosine Methyltransferases as Tumor Markers
Current Genomics CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Current Pharmaceutical Design